Management of hyperlipidemia in the elderly

Cardiovascular Reviews and Reports

Volumn 23, Issue 6, 2002, Pages 361-370

  Aronow, Wilbert S ^a   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ARTERY DISEASE; ATHEROSCLEROTIC PLAQUE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CHOLESTEROL INTAKE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DIET; ELDERLY CARE; FLUSHING; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; METABOLIC DISORDER; MORTALITY; MYOSITIS; PEPTIC ULCER; RESTENOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0036278216     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Cardiovascular disease in the elderly
2. Serum cholesterol as a prognostic factor after MI: The Framingham Study
3. Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged Δ62 years
4. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease
5. HDL cholesterol predicts coronary heart disease mortality in older persons
6. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly, The Bronx Aging Study
7. Serum lipids and lipoproteins in advanced age: Intra-individual changes
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S)
10. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
11. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering
12. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
13. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) Trial
14. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial
15. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
17. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID Trial
18. Effects of pravastatin in 3260 patients with unstable angina: Results from the LIPID study
19. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins versus no lipid-lowering drug
20. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes an observational study
21. Effects of atorvastatin on early recurrent ischemic events in acute coronary, syndromes. The MIRACL Study: A randomized controlled trial
22. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations
23. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
24. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial
25. Effect of statin therapy on restenosis after coronary stent implantation
26. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
27. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
28. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
29. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
30. Cholesterol reduction rapidly improves endothelial function after acute coronary, syndromes. The RECIFE (Reduction of Cholesterol) in Ischemia and Function of the Endothelium) Trial
31. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammnation/CRP Evaluation (PRINCE): A randomized trial and cohort study
32. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
33. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
34. Prognostic significance of silent myocardial ischemia in patients >61 years of age with extracranial internal or common carotid arterial disease with and without previous myocardial infarction
35. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction
36. Forty-five-month follow-up of extracranial carotid arterial disease for new coronary events in elderly patients
37. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/d/L
38. Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women
39. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
40. Reductase inhibitor monotherapy and stroke prevention
41. Risk factors for extracranial internal or common carotid arterial disease in elderly patients
42. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
43. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
44. Association of coronary risk factors with progression of valvular aortic stenosis in older persons
45. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons
46. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
47. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
48. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study
49. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin
50. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
51. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial
52. Lovastatin and extended-release niacin combination product. The first drug combination for the treatment of hyperlipidemia
53. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease
54. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
55. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
56. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
57. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
58. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol